Adaptive Biotechnologies Stock

adaptivebiotech.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $561.37MM

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register To Buy and Sell Shares

For more details on financing and valuation for Adaptive Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Adaptive Biotechnologies’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Adaptive Biotechnologies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

JULIE RUBINSTEIN
President
SEAN NOLAN
Chief Technical Officer
CHAD ROBINS
Chief Executive Officer, Co-founder
LANCE BALDO
Chief Medical Officer
HARLAN ROBINS, PHD
Chief Scientific Officer, Co-founder
CHAD COHEN
Chief Financial Officer

Board Members

PETER NEUPERT
Operating Partner at Health Evolution Partners
MIKE PELLINI, MD
MICHELLE GRIFFIN
Adaptive Biotechnologies
ANDRIS ZOLTNERS
Self
KEVIN CONROY
DAVID GOEL
Matrix Capital Management
CHAD ROBINS
Adaptive Biotechnologies
ERIC DOBMEIER
Adaptive Biotechnologies
ROBERT HERSHBERG, MD, PhD
Celgene

News Highlights

Adaptive Biotechnologies Revenues Rise 26 Percent in Q4, 57 Percent in 2021
Fourth quarter sequencing revenue increased 81 percent to $23.1 million year over year, while development revenue dropped 15 percent to $14.9 million.
People in the News: New Appointments at BD, Adaptive Biotechnologies, ChromaCode, More
Adaptive Biotechnologies Q1 Revenues up 84 Percent, Beat Analyst Estimates
Updated on: Apr 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.